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TTP and OS were female gender, the absence of smoking history, and 
adenocarcinoma histology. As expected, those treated with Erlotinib in 
the ﬁrst line setting had signiﬁcantly longer TTP than further lines (7.4 
vs. 4.4; p<0.001). In the multivariate analysis only non smoking history 
remained as predictive factor for longer TTP and survival (p<0.0001). 
Most frequent reported adverse events were rash (62.9%; 12.9% grade 
3/4), asthenia (37.1%; 9.2% grade 3/4) and diarrhea (33.3%; 6.1% 
grade 3/4).
Conclusions: This interim analysis of a subset of elderly patients with 
advanced or metastatic NSCLC treated with Erlotinib in a real-life 
clinical setting conﬁrms the good tolerability and promising activity. It 
is worthwhile mentioning the beneﬁt in survival obtained by chemona-
ïve elderly patients. Therefore Erlotinib is an effective treatment for 
elderly patients with advanced NSCLC, even as a ﬁrst-line treatment. A 
randomized phase III study intended for elderly patients with Erlotinib 
is warranted.
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Background: Erlotinib, a tyrosine kinase inhibitor, has been shown to 
improve the survival and quality of life in patients with non-small cell 
lung cancer (NSCLC) after ﬁrst or second-line chemotherapy. Asian 
origin, adenocarcinoma histologic type, female gender, lack of tobacco 
use, and expression of EGFR have been described as signiﬁcant inde-
pendent predictors of response to erlotinib. Although tobacco use is 
considered a major cause of NSCLC, other factors are involved in its 
pathogenesis. In underdeveloped countries such as Mexico, wood and 
other solid fuels are still used for cooking and heating. The pathophysi-
olocial mechanisms of wood smoke exposure (WSE) as a potential risk 
factor for the development of NSCLC are still unknown. 
Methods: In this study, 135 patients with histologically proven NSCLC 
with poor performance status were treated with erlotinib after ﬁrst or 
second-line chemotherapy. Clinical and pathological characteristics 
were associated with response to treatment. 
Results: We found a global response to erlotinib in 45 patients (31.3%, 
CI 95% 23.5-39.1), stable disease in 31.9% and progression in 30.6%. 
Clinical improvement was observed in 56.5%. The clinical features 
associated with response to erlotinib in the univariate analysis were 
female gender (44.4 vs. 20.6%, p=0.003), no tobacco use (48.4 vs. 
19.7%, p<0.001). Borderline statistical signiﬁcance was observed with 
adenocarcinoma histological type (34.3 vs. 16%, p=0.086). However, 
in the logistic regression analysis only the histological type (p=0.049) 
and WSE (p=0.001) showed statistical signiﬁcance. The factors as-
sociated to an improved progression-free survival(PFS) in the Cox 
multivariate analysis were adenocarcinoma histologic type (7.9±0.7 vs 
2.2±0.4 months, p= 0.02), female gender (8.4±0.7 vs 4.4±1.6 months, 
p= 0.02) and WSE (17.56±4.17 vs 4.8±0.7 months, p< 0.001). 
Conclusion: WSE is associated with response to erlotinib in patients 
with NSCLC and may indicate an improvement in PFS. The EGFR 
mutation is probably involved in the development of NSCLC in non-
smokers with WSE. 
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Background: IL-20 is a pleiotrophic member of the IL-10 family and 
plays a role in skin inﬂammation and the development of haematopoi-
etic cells. It has potent angiogenic, inﬂammatory and chemo-attrac-
tive characteristics with an involvement in rheumatoid arthritis and 
atherosclerosis. It activates STAT3, which in turn promotes prolifera-
tion, apoptosis resistance and immune tolerance. STAT3 activation 
is recognised as an important link between inﬂammation and cancer. 
It can function through IL-20Rα, IL-20Rβ and IL-22R1. Decreased 
expression of IL-20Rα in lung tissues of non-small lung cancer patients 
correlated with an increase in disease free survival. 
Methods: A panel of cell lines were examined for the expression of 
IL-20, IL-20Rα and IL-20Rβ at the mRNA and protein level. This 
included three normal (HBEC 3, 4 & 5) and two lung cancer (A549-
adenocarcinoma & SK-MES-1- squamous cell carcinoma) cell lines. 
The effects of a histone deacetylase inhibitor, Trichostatin A, (TSA-
250ng/ml) and cycloheximide (10μg/ml) on the expression of the IL-20 
family were examined. A CHiP assay was carried out to investigate 
the effect of TSA on the IL-20 promoter. Tumour and normal matched 
tissue from patients were examined at the mRNA and protein level for 
the IL-20 receptors. 
Results: The mRNA expression pattern of IL-20 was different in the 
normal and lung cancer cell lines. There was moderate to high expres-
sion in the three normal cell lines compared with low to moderate lev-
els in the cancer cell lines. A similar trend was observed with IL-20Rα 
and IL-20Rβ. The anti-angiogenic properties of IL-20 have previously 
been demonstrated in the lung. We investigated the effect of TSA on 
IL-20 expression. IL-20 was induced by TSA treatment in all cell lines 
and super-induced by cycloheximide in A549 and HBEC 4. Results 
from a CHiP assay performed on A549 cells demonstrates that the ef-
fect of TSA is and early and immediate response. The effect of TSA on 
the two receptors at mRNA level was much less pronounced on the cell 
lines with the exception of HBEC 4, which showed a minor increase 
of both with treatment. Further analysis of IL-20 and the receptors in 
clinical (adenocarcinoma and squamous cell carcinoma) samples re-
vealed a somewhat different pattern between the two lung cancer types. 
At the mRNA level, IL-20 was downregulated in adenocarcinoma and 
upregulated in squamous samples. There was an increase in IL-20Rβ 
mRNA and protein in both tumour types. A signiﬁcant difference 
was observed in IL-20Rα expression between the tumour types. In 
adenocarcinomas, IL-20Rα was predominantly downregulated at the 
mRNA level, with minimum detection at the protein level. However, in 
squamous samples the receptor was upregulated in tumours at both the 
mRNA and protein level. 
